XML 114 R100.htm IDEA: XBRL DOCUMENT
v3.24.0.1

BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details) |  |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 12, 2023 USD ($) | Aug. 02, 2022 USD ($) $ / shares shares | May 02, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) test $ / shares | Jun. 23, 2021 USD ($) | Apr. 14, 2021 USD ($) $ / shares shares | Jan. 11, 2021 USD ($) shares | Jan. 05, 2021 USD ($) $ / shares shares | May 31, 2022 shares | Dec. 31, 2021 USD ($) $ / shares shares | Apr. 30, 2021 USD ($) shares | Jan. 31, 2021 USD ($) shares | Mar. 31, 2021 USD ($) | Dec. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2021 USD ($) $ / shares | Aug. 23, 2023 USD ($) | May 01, 2022 USD ($) | May 03, 2021
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued, price per share (in usd per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 73.98 |  |  |  |  |  |
Contingent consideration, liability |  |  |  | $ 359,021,000 |  |  |  |  |  | $ 359,021,000 |  |  |  | $ 288,657,000 | $ 306,927,000 | $ 359,021,000 | $ 359,021,000 |  |  |
Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 231,312,000 | 206,823,000 |  | 339,226,000 |  |  |
Remeasurement of contingent consideration liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  | (18,044,000) | (56,617,000) |  | 6,360,000 |  |  |
Stock-based compensation |  |  |  |  |  |  |  |  |  |  |  |  |  | 231,312,000 | 206,823,000 |  | 253,063,000 |  |  |
Stock issued during period, value, acquisitions |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,675,000 | 14,792,000 |  | 1,355,170,000 |  |  |
Consideration transferred, net of cash acquired |  |  |  |  |  |  |  |  |  |  |  |  |  | 52,413,000 | 14,686,000 |  | 499,730,000 |  |  |
Noncash or part noncash divestiture, amount of consideration received, fair value | $ / shares |  | $ 6.70 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 640,396,000 | $ 706,240,000 |  |  |  |  |
Period of lab testing services |  | 24 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Other operating income (loss) |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract with Customer, Receivable, after Allowance for Credit Loss |  |  |  |  |  |  |  |  |  |  |  |  |  | 31,600,000 |  |  |  |  |  |
Contract with Customer, Asset, after Allowance for Credit Loss |  |  |  |  |  |  |  |  |  |  |  |  |  | 41,700,000 | $ 0 |  |  |  |  |
TARDIS Technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset acquisition, consideration transferred |  |  |  |  |  |  | $ 52,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire productive assets |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire productive assets (in shares) | shares |  |  |  |  |  |  | 191,336 |  |  |  |  |  |  |  |  |  |  |  |  |
Stock issued to acquire productive assets, value |  |  |  |  |  |  | $ 27,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Payments contingent on milestones |  |  |  |  |  |  | $ 45,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Oncotype DX Genomic Prostate Score Test |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total consideration |  | $ 29,631,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or part noncash divestiture, amount of consideration received, shares | shares |  | 691,171 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disposal group, contingent consideration arrangements, range of outcomes, value, high |  | $ 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 82,500,000 |  |
Finite-lived Intangible assets, net |  | $ 42,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disposal group, not discontinued operation, gain (loss) on disposal |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,200,000 |  |  |  |  |
Disposal Group, Contingent Consideration Arrangements, Gain (Loss) |  |  |  |  |  |  |  |  |  |  |  |  |  | 73,300,000 |  |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disposal Group, Contingent Consideration Arrangements, Gain (Loss) |  |  |  |  |  |  |  |  |  |  |  |  |  | 73,300,000 |  |  |  |  |  |
Thrive |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment owned, fair value |  |  |  |  |  |  |  | $ 12,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Business combination, equity interest in acquiree, remeasurement gain |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,600,000 |  |  |  |  |  |  |
Remeasurement of contingent consideration liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,200,000 |  |  |
Customer relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,111,000 | $ 3,556,000 |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted Average Remaining Life (Years) |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 years | 8 years |  |  |  |  |
Trade name |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 76,097,000 | $ 83,347,000 |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted Average Remaining Life (Years) |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 years 7 months 6 days | 12 years 6 months |  |  |  |  |
General and administrative |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 103,757,000 | $ 91,212,000 |  | $ 216,952,000 |  |  |
Investment Income | Thrive |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, equity interest in acquiree, remeasurement gain |  |  |  |  |  |  |  |  |  |  |  |  | 30,500,000 |  |  |  |  |  |  |
OmicEra |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  | $ 19,408,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issued to acquire business (in shares) | shares |  |  |  |  |  |  |  |  | 265,186 |  |  |  |  |  |  |  |  |  |  |
Shares issued, price per share (in usd per share) | $ / shares |  |  | $ 55.78 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payment obligations |  |  | $ 6,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  | 4,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average remaining useful life of finite-lived intangible asset (in years) |  |  | 16 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of stock issued in acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 14,792,000 |
Common stock issued |  |  | $ 14,792,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OmicEra Diagnostics Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issued to acquire business (in shares) | shares |  |  |  |  |  |  |  |  | 265,186 |  |  |  |  |  |  |  |  |  |  |
PreventionGenetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  | $ 185,381,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issued to acquire business (in shares) | shares |  |  |  |  |  |  |  |  |  | 1,070,410 |  |  |  |  |  |  |  |  |  |
Shares issued, price per share (in usd per share) | $ / shares |  |  |  | $ 78.71 |  |  |  |  |  | $ 78.71 |  |  |  |  |  | $ 78.71 | $ 78.71 |  |  |
Number of tests provided | test |  |  |  | 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  |  |  | $ 101,129,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, cash withheld |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,300,000 |  |  |  |  |
Fair value of stock issued in acquisition |  |  |  | 84,252,000 |  |  |  |  |  | $ 84,252,000 |  |  |  |  |  | $ 84,252,000 | $ 84,252,000 |  |  |
Common stock issued |  |  |  | 84,252,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PreventionGenetics | Payment 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  |  |  | $ 85,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ashion Analytics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  | $ 109,999,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issued to acquire business (in shares) | shares |  |  |  |  |  | 125,444 |  |  |  |  | 125,444 |  |  |  |  |  |  |  |  |
Shares issued, price per share (in usd per share) | $ / shares |  |  |  |  |  | $ 129.33 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  |  |  |  |  | $ 74,775,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of stock issued in acquisition |  |  |  |  |  |  |  |  |  |  | $ 16,224,000 |  |  |  |  |  |  |  |  |
Common stock issued |  |  |  |  |  | 16,224,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ashion Analytics | Commercial Launch Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  | 19,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional cash consideration to be paid |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ashion Analytics | MRD Product Revenue Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  | 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue milestone |  |  |  |  |  | $ 500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Thrive |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  | $ 2,187,054,000 |  |  |  |  |  |  |  |  |  |  |  |
Equity issued to acquire business (in shares) | shares |  |  |  |  |  |  |  | 9,323,266 |  |  |  | 9,323,266 |  |  |  |  |  |  |  |
Shares issued, price per share (in usd per share) | $ / shares |  |  |  |  |  |  |  | $ 127.79 |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  | $ 450,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Cash |  |  |  |  |  |  |  | 584,996,000 |  |  |  |  |  |  |  |  |  |  |  |
Fair value of stock issued in acquisition |  |  |  |  |  |  |  | 1,190,000,000 |  |  |  | $ 1,191,420,000 |  |  |  |  |  |  |  |
Common stock issued |  |  |  |  |  |  |  | 1,175,431,000 |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire businesses and accelerated vesting of awards |  |  |  |  |  |  |  | 590,200,000 |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  |  | 166,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Compensation consideration assumed |  |  |  |  |  |  |  | 197,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Compensation consideration assumed and allocated to consideration transferred |  |  |  |  |  |  |  | 52,200,000 |  |  |  |  |  |  |  |  |  |  |  |
Compensation consideration assumed and deemed compensatory |  |  |  |  |  |  |  | 144,800,000 |  |  |  |  |  |  |  |  |  |  |  |
Non-cash stock-based compensation expense |  |  |  |  |  |  |  | 65,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Share based compensation, costs not yet recognized |  |  |  |  |  |  |  | $ 79,800,000 |  |  |  |  |  |  |  |  |  |  |  |
Share conversion ratio |  |  |  |  |  |  |  | 0.06216 |  |  |  |  |  |  |  |  |  |  |  |
Business combination, pro forma loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 255,000,000 |  |  |  |
Acquisition related costs |  |  |  |  |  |  |  |  |  |  |  |  | 10,300,000 |  |  |  | 10,300,000 |  |  |
Stock-based compensation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,000,000 |  |  |
Additional benefit charges |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,900,000 |  |  |
Thrive | Employees with Qualifying Termination Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-cash stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |  | 13,500,000 |  |  |  |  |  |  |
Thrive | Fair Value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  | $ 352,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Thrive | FDA Approval |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  | 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Thrive | CSM Coverage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Thrive | Allocated to Consideration Transferred | Fair Value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  | 331,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Thrive | Allocated to Previous Ownership Interest | Fair Value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  | 6,400,000 |  |  |  |  |  |  |  |  |  |  |  |
Thrive | Allocated to Compensation | Fair Value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  | 14,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Thrive | Compensation Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payment obligations |  |  |  |  |  |  |  | 18,200,000 |  |  |  |  |  |  |  |  |  |  |  |
Thrive | General and administrative |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Incremental share based compensation expense |  |  |  |  |  |  |  | 16,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  |  | $ 5,200,000 |  |  |  |  |  |  |  |  |  |  |  |
Non-cash stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 86,200,000 |  |  |  | $ 86,200,000 |  |  |
PFS Genomics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  | $ 33,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of equity acquired |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90.00%
Equity interest in acquiree after subsequent acquisition |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Resolution Bioscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price | $ 54,202,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology | 26,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | 52,527,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued | $ 1,675,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method | 4.6 million |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory | $ 2,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method | 4.6 million |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory | $ 2,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method | 4.6 million |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares + References No definition available. + Details
Name: | exas_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix: | exas_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Issued Exchange Ratio + References No definition available. + Details
Name: | exas_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssuedExchangeRatio
Namespace Prefix: | exas_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Consideration Transferred, Cash Withheld For Future Claims And Adjustments + References No definition available. + Details
Name: | exas_BusinessCombinationConsiderationTransferredCashWithheldForFutureClaimsAndAdjustments
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory + References No definition available. + Details
Name: | exas_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCompensatory
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Additional Payment + References No definition available. + Details
Name: | exas_BusinessCombinationContingentConsiderationAdditionalPayment
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Revenue Milestone + References No definition available. + Details
Name: | exas_BusinessCombinationContingentConsiderationRevenueMilestone
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-based Compensation + References No definition available. + Details
Name: | exas_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensation
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation Allocated to Consideration Transferred + References No definition available. + Details
Name: | exas_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensationAllocatedToConsiderationTransferred
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation, Deemed Compensatory + References No definition available. + Details
Name: | exas_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensationDeemedCompensatory
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disposal Group, Contingent Consideration Arrangements, Gain (Loss) + References No definition available. + Details
Name: | exas_DisposalGroupContingentConsiderationArrangementsGainLoss
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disposal Group, Contingent Consideration Arrangements, Range Of Outcomes, Value, High + References No definition available. + Details
Name: | exas_DisposalGroupContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Noncash or Part Noncash Divestiture, Amount of Consideration Received, Fair Value + References No definition available. + Details
Name: | exas_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedFairValue
Namespace Prefix: | exas_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Noncash or Part Noncash Divestiture, Amount of Consideration Received, Shares + References No definition available. + Details
Name: | exas_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedShares
Namespace Prefix: | exas_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Tests Provided + References No definition available. + Details
Name: | exas_NumberOfTestsProvided
Namespace Prefix: | exas_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents potential future payments still contingent upon achievement of milestones under a collaborative arrangement. + References No definition available. + Details
Name: | exas_PaymentsContingentOnMilestonesPayable
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payments To Acquire Businesses And Accelerated Vesting Of Awards + References No definition available. + Details
Name: | exas_PaymentsToAcquireBusinessesAndAcceleratedVestingOfAwards
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period Of Lab Testing Services + References No definition available. + Details
Name: | exas_PeriodOfLabTestingServices
Namespace Prefix: | exas_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The method of determining the fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5 + Details
Name: | us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3 + Details
Name: | us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cost not yet recognized for nonvested award under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value of investment in security owned. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12 Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedAtFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period expense related to postemployment benefits. + References No definition available. + Details
Name: | us-gaap_PostemploymentBenefitsPeriodExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of noncash expense for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_ShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition An excess of the fair value of the modified award over the fair value of the award immediately before the modification. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of stock issued pursuant to acquisitions during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueAcquisitions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=exas_TARDISTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=exas_OncotypeDXGenomicProstateScoreTestMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=exas_ThriveEarlierDetectionCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_InvestmentIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=exas_OmicEraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=exas_OmicEraDiagnosticsAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=exas_PreventionGeneticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exas_BusinessAcquisitionPaymentTrancheAxis=exas_BusinessAcquisitionPaymentTrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=exas_AshionAnalyticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_CommercialLaunchMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_MRDProductRevenueMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=exas_ThriveEarlierDetectionCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=exas_EmployeesWithQualifyingTerminationEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_FDAApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_CenterForMedicareAndMedicaidServicesCMSCoverageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_AllocatedToConsiderationTransferredMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_AllocatedToPreviousOwnershipInterestMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_AllocatedToCompensationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=exas_CompensationExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=exas_PFSGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=exas_ResolutionBioscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |